Genomic testing for pancreatic cancer in clinical practice as real-world evidence

Comprehensive validation of liquid-based cytology specimens for next-generation sequencing in cancer genome analysis

“…For MCF-7 cells, the QIAseq Human Breast Cancer Panel was also used to construct the NGS library. The above cancer panel has been clinically implemented as the PleSSision test (formerly known as the CLHURC test, Keio University PleSSision Group, Tokyo, Japan) [19]. For the LBC samples from breast cancer tissues obtained at Hokuto Hospital, an NGS library was constructed using the QIAseq Human Breast Cancer Panel.…”

Clinical implications of next‐generation sequencing‐based panel tests for malignant ovarian tumors

“…2,3 We previously reported that only 10% of pancreatic cancer patients who underwent a targeted amplicon exome sequencing for 160 cancer-related genes (PleSSision-160) could be treated with therapeutic agents based on the results of genomic testing. 4 Clinical sequencing for ovarian cancer is necessary due to its poor prognosis; however, reports regarding ovarian cancer are scarce. 2,5,6 Currently, there is no comprehensive report on genomic testing of malignant ovarian tumors.…”

Precision Oncology in Pancreatic Cancer. From Surgery- to Genetic-Based Chemotherapy

“…Recent international efforts have characterized the genomic landscape of pancreatic tumors 14 . The studies have shown that a significant fraction of these patients presents predictive germline and somatic biomarkers that could help with diagnosis and prognosis 15 . Besides the well-known mutations in KRAS, TP53, CDKN2A, and SMAD4, a long list of less frequent mutations has been discovered, including chromatin-regulating genes such as MLL, MLL2, MLL3, and ARID1A; axon-guidance genes such as ROBO1, 2, and 3; DNA-damage genes such as ATM; and other novel genes such as KDM6A, PREX2, and RNF43 16 .…”